Chairperson F. Cavalli

L. Mazzucchelli The provisional lymphoma entities in the WHO classification 10.30-11.30
A. Tzankov How many molecular types of DLBCL? 11.30-12.00
L. Ceriani PET metrics replacing visual analysis in NHL? 12.30-13.30

12.30-13.30 Lunch

Chairperson E. Zucca

A. Moccia / L.Mazzucchelli Tumor board: Difficult diagnoses 13.30-14.30
L. De Leval What’s new as regards pathology in T cell lymphomas? 14.30-15.00
S. Luminari What’s new clinically in non cutaneous T cell lymphomas? 15.00-15.30

15.30-15.50 Break

L. Pasqualucci The epigenetic regulation of the germinal center: Implications for lymphoma pathogenesis, immune evasion and treatment 15.50-16.30
H. Beltraminelli Cutaneous T-cell lymphomas 16.30-17.00

17:00-18:00 Discussion of cases of participants

Chairperson A. Moccia

P. Johnson Hodgkin lymphomas: soon 100% cured 8.30-9.15
E. Zucca What’s new in PMBCL? 9.15-9.35
F. Cavalli What’s new in follicular lymphomas? 9.35-10.00
D. Rossi What’s new in marginal zone lymphomas? 10.00-10.35

10.30-11.00 Break

Targeted therapies

A. Stathis – State of the art in NHL 11.00-12.00
F. Bertoni – Mechanisms of resistance
D. Rossi – The paradigm of CLL
D. Robbiani From chronic infection to genomic instability and B-cell lymphoma 12.00-12.45

12.45-14.00 Lunch

Chairperson D. Rossi

A. Moccia The standard therapy of DLBCL (including CNS prophylaxis) 14.00-14.45
U. Novak What’s new in mantle cell lymphoma? 14.45-15.10

15.10-15.45 Break

Chairperson D. Rossi

S. Luminari Burkitt and high grade lymphomas with and without myc and bcl2 rearrangements 15.45-16.15
U. Novak Immunotherapy in NHL: State of the art 16.15-17.00

17:00-18:00 Discussion of cases of participants

Chairperson F. Cavalli

 

Discussion of cases of participants 9.00-10.00
E. Lerch Myeloma 10.00-10.40
B. Gerber Amyloidosis and other gammopathies of clinical significance 10.40-11.15
F. Cavalli Concluding remarks & End of the meeting 11.15-11.30

Download Program